{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:08:35Z","timestamp":1772921315186,"version":"3.50.1"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.2169\/internalmedicine.5949-25","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:10:23Z","timestamp":1753308623000},"page":"690-697","source":"Crossref","is-referenced-by-count":0,"title":["Intrathoracic Rhabdoid Tumors Showing Rapid Progress in Patients with a History of Immune-suppressive Therapies for Hematological Diseases"],"prefix":"10.2169","volume":"65","author":[{"given":"Motoko","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Imi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanazawa University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanazawa University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Le Loarer F, Watson S, Pierron G, et al. <i>SMARCA4<\/i> inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47: 1200-1205, 2015.","DOI":"10.1038\/ng.3399"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yoshida A, Kobayashi E, Kubo T, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 30: 797-809, 2017.","DOI":"10.1038\/modpathol.2017.11"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tagal V, Wei S, Zhang W, et al. <i>SMARCA4<\/i>-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun 8: 14098, 2017.","DOI":"10.1038\/ncomms14098"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fillmore CM, Xu C, Desai PT, et al. EZH2 inhibition sensitizes <i>BRG1<\/i> and <i>EGFR<\/i> mutant lung tumours to TopoII inhibitors. Nature 520: 239-242, 2015.","DOI":"10.1038\/nature14122"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Xue Y, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4\/6 inhibition in non-small cell lung cancer. Nat Commun 10: 557, 2019.","DOI":"10.1038\/s41467-019-08380-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Haberecker M, Buhler MM, Mendieta AP, et al. Molecular and immunophenotypic characterization of <i>SMARCB1<\/i> (INI1) - deficient intrathoracic Neoplasms. Mod Pathol 35: 1860-1869, 2022.","DOI":"10.1038\/s41379-022-01133-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Herpel E, Rieker RJ, Dienemann H, et al. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol 26: 47-51, 2017.","DOI":"10.1016\/j.anndiagpath.2016.10.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Orvis T, Hepperla A, Walter V, et al. BRG1\/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. Cancer Res 74: 6486-6498, 2014.","DOI":"10.1158\/0008-5472.CAN-14-0061"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 15: 231-247, 2020.","DOI":"10.1016\/j.jtho.2019.10.023"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zagni M, Marando A, Negrelli M, et al. SMARCB1\/INI1-deficient undifferentiated tumour of the thorax: a case report and review of the literature. Pathologica 116: 163-169, 2024.","DOI":"10.32074\/1591-951X-955"},{"key":"11","unstructured":"11. In: WHO Classification of Tumours. 5th ed. WHO Classification of Tumours Editorial Board, Ed. Thoracic Tumours. IARC, Lyon, 2021."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Reisman D, Glaros S, Thompson EA. The SWI\/SNF complex and cancer. Oncogene 28: 1653-1668, 2009.","DOI":"10.1038\/onc.2009.4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 35: e47-e63, 2011.","DOI":"10.1097\/PAS.0b013e31822b325b"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sasaki M, Sato Y, Nakanuma Y. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. Histopathology 83: 298-309, 2023.","DOI":"10.1111\/his.14932"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kohashi K, Yamamoto H, Yamada Y, et al. SWI\/SNF chromatin-remodeling complex status in SMARCB1\/INI1-preserved epithelioid sarcoma. Am J Surg Pathol 42: 312-318, 2018.","DOI":"10.1097\/PAS.0000000000001011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schwartz CJ, Pareja F, da Silva EM, et al. Histologic and genomic features of breast cancers with alterations affecting the SWI\/SNF (SMARC) genes. Mod Pathol 34: 1850-1859, 2021.","DOI":"10.1038\/s41379-021-00837-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Metzner B, Muller TH, Casper J, et al. Secondary malignancies after autologous stem cell transplantations in patients with malignant lymphoma and multiple myeloma. Eur J Haematol 114: 536-544, 2025.","DOI":"10.1111\/ejh.14355"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tichelli A. Secondary neoplasia (other than PTLPS). In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. 8th ed. Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, Eds. Springer, Cham, 2024.","DOI":"10.1007\/978-3-031-44080-9_47"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113: 1175-1183, 2009.","DOI":"10.1182\/blood-2008-05-158782"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117: 316-322, 2011.","DOI":"10.1182\/blood-2010-07-294629"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5949-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:45:59Z","timestamp":1772855159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5949-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5949-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"5949-25"}}